ROS1 FUSION GENES: POTENTIAL DRUG TARGETS IN NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Davies, Kurtis D. [1 ]
Le, Anh T. [1 ]
Theodoro, Mariana F. [1 ]
Skokan, Margaret C. [1 ]
Aisner, Dara L. [2 ]
Terracciano, Luigi M. [3 ]
Incarbone, Matteo [4 ]
Roncalli, Massimo [4 ]
Cappuzzo, Federico [5 ]
Camidge, Ross D. [1 ]
Doebele, Robert C. [1 ]
Garcia, Marileila V. [1 ]
机构：
[1] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA
[2] Univ Colorado, Sch Med, Dept Pathol, Boulder, CO 80309 USA
[3] Univ Basel Hosp, Basel, Switzerland
[4] Ist Clin Humanitas, Rozzano, Italy
[5] Livorno Hosp, Livorno, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S146 / S146
页数：1
相关论文
共 50 条
  • [31] Comprehensive Profiling of ROS1 Fusions in Chinese Non-Small Cell Lung Cancer Patients
    Xu, H.
    Fan, X.
    Tian, K.
    Liang, X.
    Li, J.
    Cheng, Y.
    Zhang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S686 - S686
  • [32] ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
    Roskoski, Robert, Jr.
    PHARMACOLOGICAL RESEARCH, 2017, 121 : 202 - 212
  • [33] Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer
    Li, Ziming
    Shen, Lan
    Ding, Ding
    Huang, Jia
    Zhang, Jie
    Chen, Zhiwei
    Lu, Shun
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 987 - 995
  • [34] Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion
    Watanabe, Junko
    Furuya, Naoki
    Fujiwara, Yutaka
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : E66 - E69
  • [35] Clinical Validation of a Real Time PCR Assay for the Detection of ROS1 Fusion in Chinese Non-Small Cell Lung Cancer
    Zhu, G.
    Huang, G.
    Song, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2244 - S2245
  • [36] Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion
    Li, ZhiFeng
    Lin, Yingcheng
    Chi, Xiuying
    Xu, Mian
    Wang, Hongbiao
    LUNG CANCER, 2021, 153 : 174 - 175
  • [37] Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
    Ahn, M.
    Cho, B. C.
    Siena, S.
    Drilon, A.
    De Braud, F.
    Krebs, M.
    John, T.
    Karapetis, C.
    Johnson, A.
    Chow-Maneval, E.
    Multani, P.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1783 - S1783
  • [38] Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer:trials and treatment options
    Arpita Desai
    Smitha P.Menon
    Grace K.Dy
    Cancer Biology & Medicine, 2016, (01) : 77 - 86
  • [39] Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
    Desai, Arpita
    Menon, Smitha P.
    Dy, Grace K.
    CANCER BIOLOGY & MEDICINE, 2016, 13 (01) : 77 - 86
  • [40] Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer:trials and treatment options
    Arpita Desai
    Smitha PMenon
    Grace KDy
    Cancer Biology & Medicine, 2016, 13 (01) : 77 - 86
12345